expansion. Summary of Financial Statement of Position As of 30 Sep 2018 As of 31 Dec 2017 Change MB. % MB. % MB. % Assets Cash and cash equivalents 17.7 0.7% 6 0.2% 11.7 195.0% Trade and other receivables
Million from loss on change in fair value less cost to sale of biological assets, resulted from decreased fair price of fattening pigs from the end of Q2/2019 to Q3/2019. Financial Cost Financial cost in
the performance and the financial status for the year 2019 ended December 31, 2019 of the Company and its subsidiaries, as shown below: (Unit : Thousand Baht) 2019 2018 Change %Change Revenue 910,707
results for the nine-month period of 2019, change of rate more than 20 percent Dear Director and Manager The Stock Exchange of Thailand According to the resolution of the Board of Directors of DOD Biotech
data-driven supervision whereby responses to change will be faster and risks exposed to investors and the financial system will be managed in a more timely manner. In so doing, we change the mindset and
subsidiary Aphakorn Industries Company Limited change status from an associate to a subsidiary which receive repayment from PA Capital Company Limited is making a profit from fair value adjustment of 6.14
change in the first half of this year as well as increasing number of beds in service. Operation : Consolidated Profit & Loss Statement 4Q 4Q % 12 mth 12 mth % Unit : THB million 2018 2017 change 2018 2017
to submit our management’s discussion and analysis for the fiscal year ended December 31, 2019, as follows: For the year ended December 31 Change 2019 2018 MB MB % Sales revenue 371.33 316.83 17.20
Statement 2Q 2Q % 6 mth 6 mth % Unit : THB million 2018 2017 change 2018 2017 change Revenue from non-social security 212.10 178.03 19% 430.34 355.30 21% Revenue from social security 171.37 153.92 11% 336.06